FDA Chief Faces FIRING—Pro-Life Groups Demand Action

The FDA’s continued approval of abortion pills under Trump’s administration threatens to fracture the Republican base as frustrated pro-life voters who delivered his 2024 victory now question whether their voices matter in Washington.

Story Snapshot

FDA Commissioner Dr. Marty Makary faces mounting calls for removal after approving second generic mifepristone despite pro-life safety concerns
Live Action investigation reveals 27 Planned Parenthood sites skipping required ultrasounds and blood tests, while new report claims adverse events 22 times higher than clinical trials
Mike Pence calls HHS Secretary RFK Jr.’s handling a “complete betrayal” as 20+ GOP attorneys general sue to reinstate safeguards
Trump White House remains silent on leadership changes, risking midterm support from core constituency that prioritized abortion restrictions

FDA Approvals Spark Conservative Outcry

The FDA approved a second generic version of mifepristone in early May 2026, intensifying backlash from pro-life advocates who expected President Trump’s appointees to reverse course on abortion pill access. FDA Commissioner Dr. Marty Makary defends the decision as evidence-based, but critics point to what they view as dangerous regulatory shortcuts. The agency expanded access in 2016 and 2021, allowing telehealth prescriptions and mail delivery without in-person visits, a policy that survived legal challenges even after the Supreme Court overturned Roe v. Wade in 2022. These federal rules effectively undermine abortion bans in 13 states, fueling accusations that unelected bureaucrats prioritize ideology over state sovereignty and women’s safety.

Safety Data Fuels Regulatory Compliance Questions

A report from the Ethics and Public Policy Center claims mifepristone adverse events occur at an 11 percent rate, dramatically higher than the less than 0.5 percent cited on FDA labels and 22 times the rate observed in clinical trials. Live Action released an investigative video in April 2026 showing 27 Planned Parenthood facilities distributing the pills via telehealth without conducting required ultrasounds to confirm gestational age or Rh blood tests to prevent complications. The organization submitted a formal letter demanding HHS and FDA suspend approvals and eliminate mail-order distribution. HHS Secretary Robert F. Kennedy Jr. ordered a study of adverse events, but the agency’s six-month timeline drew criticism from activists who argue lives hang in the balance while officials delay action on what they consider clear regulatory violations.

Political Pressure Mounts on Trump Administration

Former Vice President Mike Pence declared the administration’s inaction a “complete betrayal” of pro-life voters, while Senator Josh Hawley announced he has “no confidence in FDA leadership.” Louisiana Attorney General Elizabeth Murrill leads a coalition of over 20 GOP state attorneys general suing to reinstate previous safeguards, with cases now pending before the Fifth Circuit Court of Appeals after a district judge declined to block access but noted the states presented a strong legal argument. SBA Pro-Life America and Family Research Council’s Tony Perkins warn that continued delays risk alienating the base that secured Trump’s 2024 victory. The White House has ignored December 2025 demands to fire Makary, with reports suggesting the president weighs political calculations against legal risks. Some moderate pro-life groups trust the review process, but hardline activists view bureaucratic timelines as cover for maintaining the status quo that contradicts campaign promises.

Pro-Life Voters Are Losing Patience With the FDAhttps://t.co/HsgBV8MXJW

— PJ Media (@PJMedia_com) May 9, 2026

Implications for Governance and Voter Trust

The standoff exposes a fundamental tension between federal regulatory authority and grassroots conservatives who feel governing elites dismiss their priorities once elections end. The Cato Institute warns that politicizing the FDA from any direction undermines patient autonomy and delays access to legitimate treatments, yet pro-life advocates counter that the agency already politicized approvals by loosening safeguards under previous administrations without adequate safety justification. Telehealth abortions now represent the majority of procedures post-Dobbs, making FDA policy more consequential than state laws. If Trump removes Makary or RFK Jr., he signals responsiveness to his base but risks accusations of interfering with scientific independence. Inaction preserves institutional norms but potentially costs Republican seats in the 2026 midterms as disillusioned voters conclude their government, regardless of party control, serves powerful interests over the people who elected them. This dynamic fuels the broader distrust of the deep state among Americans across the political spectrum who increasingly believe Washington operates by its own rules.